Enfuvirtide antiretroviral therapy in HIV-1 infection

References

• BoydMRuxrungthamKEnfuvirtide: Investigations on the drug interaction potential in HIV-infected patients200310th Conference on Retroviruses and Opportunistic InfectionsBoston Abstract 541
   Google Scholar
• CabreraCMarfilSGenetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38, and 43 in gp41 under long-term enfuvirtide-containing salvage regimenAIDS20062020758017053353
   PubMed Web of Science ®Google Scholar
• ChenCMatthewsTA molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivitives: implication for viral fusionJ Virol199569377177538176
   PubMed Web of Science ®Google Scholar
• ChenRKilbyJEnfuvirtideExp Opin Investig Drugs200211183743
   PubMed Web of Science ®Google Scholar
• ChurchJHughesMLong term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected childrenPediatr Infect Dis J200423713815295220
   PubMed Web of Science ®Google Scholar
• ClotetBBellosNEfficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patientsith HIV-1 infection in POWER1 and 2:a pooled subgroup analysis of data from two randomised trialsLancet200736911697817416261
   PubMed Web of Science ®Google Scholar
• ClotetBRaffiFClinical management of treatment-experienced HIV-infected patients with the fusion inhibitor enfuvirtide:consensus recommendationsAIDS20041811274615166528
   PubMed Web of Science ®Google Scholar
• D’ArrigoRCiccozziMgp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressureAIDS Res Hum Retroviruses200723129630217961119
   PubMed Web of Science ®Google Scholar
• DeeksSHohRInterruption of treatment with individual therapeutic drug classes in adults with multi-drug resistant HIV-1 infectionJ Infect Dis200519215374416206068
   PubMed Web of Science ®Google Scholar
• DeeksSLuJInterruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimenJ Infect Dis20071953879117205477
   PubMed Web of Science ®Google Scholar
• DerdeynCDeckerJSensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120J Virol20007483586710954535
   PubMed Web of Science ®Google Scholar
• FikkertVCherepanovPEnv chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitorsAntimicrob Agents Chemother20034639546212435701
   PubMed Web of Science ®Google Scholar
• FletcherCEnfuvirtide, a new drug for HIV infectionLancet200319531521
   Google Scholar
• GazzardBAntinonACombined analysis of RESIST 96 week data:durability and efficacy of tipranivir/r in treatment-experienced patients2006Eighth International Congress on Drug Therapy in HIV Infection, Poster P23Glasgow, UK
   Google Scholar
• GilksCCrowleySThe WHO public-health approach to antiretroviral treatment against HIV in resource-limited settingsLancet20063685051016890837
   PubMed Web of Science ®Google Scholar
• GottliebMSPneumocystis pneumonia – Los AngelesAm J Public Health200696980116714472
   PubMed Web of Science ®Google Scholar
• GottliebMSchroffRPneumocystis carinii pneumonia and mucosal candidiasis in previosuly healthy homosexual men:evidence of a new acquired cellular immunodeficiencyN Engl J Med19813051425316272109
   PubMed Web of Science ®Google Scholar
• GreenbergMCammackNResistance to enfuvirtide, the first fusion inhibitorJ Antimicrob Chemother2004543334015231762
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral therapy in adults and adolescents Astella News Release, http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentsGL.pdf Last accessed September 6, 2007
   Google Scholar
• HicksCChanPDurable efficacy of tipranivir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1 infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranivir RESIST studies:an analysis of combined data from two randomized open-label trialsLancet20063684667516890833
   PubMed Web of Science ®Google Scholar
• HillAMoyleGRelative antiviral efficacy of TMC114/r and tipranivir/r versus control PI in the POWER and RESIST trials200646th Interscience Conference on Antimicrobial Agents and ChemotherapySan Francisco, CA Abstract H-1386
   Google Scholar
• HolguinAFaudonJSusceptibility of HIV-1 non-B subtypes and recombinant variances to enfuvirtideJ Clin Virol2007381768017196877
   PubMed Web of Science ®Google Scholar
• HuQXBarryAPEvolution of the HIV-1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization AIDS pathogenesisJ Virol200074185872
   Web of Science ®Google Scholar
• JohnsonVBrun-VezinetFUpdate of drug resistance mutations in HIV-1:2007Top HIV Med2007141192517720996
   PubMedGoogle Scholar
• KitchenCLuJContinued evolution in gp41 after interruption of enfuvirtide in subject with advance HIV type-1 diseaseAIDS Res Hum Retroviruses2006221260617209769
   PubMed Web of Science ®Google Scholar
• LabrosseBMorand-JoubertLRole of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patientsJ Virol20068088071916912327
   PubMed Web of Science ®Google Scholar
• LalezariJHenryKEnfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South AmericaN Engl J Med200334821758512637625
   PubMed Web of Science ®Google Scholar
• LazzarinAClotetBEfficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and AustraliaN Engl J Med200334821869512773645
   PubMed Web of Science ®Google Scholar
• LuJDeeksSRapid emergence of enfuvirtide resistance in HIV-1 infected patients:results of a clonal analysisJ Acquir Immune Defic Syndr20064360416885776
   PubMed Web of Science ®Google Scholar
• LuJSistaPRelative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide T-20J Virol20047846283715078945
   PubMed Web of Science ®Google Scholar
• MatthewsTSalgoMEnfuvirtide:the first therapy to inhibit the entry of HIV-1into host CD4 lymphocytesNat Rev Drug Discovery2004321525
   PubMed Web of Science ®Google Scholar
• MelbyTSistaPCharacterization of envelope glycoprotein gp41 genotype and phenotypic susceptability to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2AIDS Res Hum Retroviruses2006223758516706613
   PubMed Web of Science ®Google Scholar
• MooreJDomsRThe entry of entry inhibitors:A fusion of science and medicineProc Natl Acad Sci USA20031001059860212960367
   PubMed Web of Science ®Google Scholar
• NegredoEBonjochACompromised immunologic recovery in treatment-experiences patients with HIV infection receiving both tenofovir disproxil fumarate and didanosine in the TORO studiesClin Infect Dis200541901516107993
   PubMed Web of Science ®Google Scholar
• NelsonMArastehKDurable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1 infected patients in the T-20 versus optimized background only 1 and 2 clinical trialsJ Acquir Immune Defic Syndr2005404041216280694
   PubMed Web of Science ®Google Scholar
• NunnAFonescaEEvolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatmentPLoS Med20074180417
   Web of Science ®Google Scholar
• PeuchantOCapdepontSPrimary resistance to enfuvirtide T20 in recently HIV-1 infected, antioretroviral-naive patients from the ANRS Aquitaine CohortAntivir Ther2007125596217668565
   PubMed Web of Science ®Google Scholar
• RayNHarrisonJClinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitorsJ Virol20078132405017251281
   PubMed Web of Science ®Google Scholar
• ReevesJFang-HuaLEnfuvirtide resistance mutations:impact on Human Immunodeficiency Virus envelope function, entry inhibitor sensitivity, and virus neutralizationJ Virol2005794991915795284
   PubMed Web of Science ®Google Scholar
• ReevesJGalloSSensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kineticsProc Natl Acad Sci USA200299162495412444251
   PubMed Web of Science ®Google Scholar
• ReynesJArastehKTORO:Ninety-six week virologic and immunologic response and safety evaluation on enfuvirtide with and optimized background of antiretroviralsAIDS Patient Care STDS2007215334317711378
   PubMed Web of Science ®Google Scholar
• RimskyLShugarsDDeterminants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptidesJ Virol199872986939444991
   PubMed Web of Science ®Google Scholar
• RomanRGonzalesDUncommon mutations at residue positions critical for enfuvirtide T-20 resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strainsJ Acquir Immune Defic Syndr200333134912794544
   PubMed Web of Science ®Google Scholar
• VillahermosaMPerez-AlvarezLPrimary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of non-B subtypes and recombinantsAIDS2003171083612700461
   PubMed Web of Science ®Google Scholar
• WildCShugarsDPeptides corresponding to a predictive alpha-helical domain of human immunodeficiency type 1 gp41 are potent inhibitors of virus infectionProc Natl Acad Sci USA199491977047937889
   PubMed Web of Science ®Google Scholar
• WizniaAChurchJSafety and efficacy for 48 weeks as part of an optimized antiretroviral regimen in pediatric Human Immunodeficiency Virus-1 patientsPediatr Infect Dis J20072679980517721374
   PubMed Web of Science ®Google Scholar
• YouleMStatsweskiSConcomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experiences HIV-infected individuals: recent data and consensus recommendationsHIV Clin Trials20067869616798623
   PubMed Web of Science ®Google Scholar
• ZhangXLinTPopulation pharmakokinetics of enfuvirtide in HIV-1 infected pediatric patients over 48 weeks of treatmentJ Clin Pharmacol2007475177
   Web of Science ®Google Scholar